Case Report: Three-year follow-up of TACE for recurrent undifferentiated pleomorphic sarcoma: sustained local control and no systemic progression [0.03%]
案例报告：TACE治疗复发的未分化多形性肉瘤3年随访：局部控制持续，无全身进展
Xiangrui Chen,Min Hu,Chengluo Hao et al.
Xiangrui Chen et al.
We report a case of recurrent undifferentiated pleomorphic sarcoma (UPS) in the right calf of a 48-year-old female patient who had undergone initial surgical resection in February 2018. The patient underwent two sessions of transcatheter ar...
Mapping the clinical trial landscape of multiple primary lung cancer in the era of precision oncology: persistent exclusion and design limitations hamper evidence-based treatment development [0.03%]
精确肿瘤学时代多原发肺癌临床试验格局的绘制：持续排除和设计限制阻碍了基于证据的治疗开发
Jianwei Shi,Linchuan Liang,Yushun Gao
Jianwei Shi
Multiple primary lung cancer (MPLC) is increasingly recognized for its clinical and biological significance, yet it remains strikingly underrepresented in clinical trials. We systematically analyzed 8,212 lung cancer trials registered betwe...
Liquid biopsy in TNBC: significance in diagnostics, prediction, and treatment monitoring [0.03%]
液体活检在三阴性乳腺癌诊断、预测和治疗监测中的意义
Jiayi Sheng,Xiaolong Zong
Jiayi Sheng
Breast cancer is the most common malignant tumor and the leading cause of mortality among women worldwide. Triple-negative breast cancer (TNBC) is recognized as t the most aggressive form of breast cancer, with a poor prognosis and a high m...
A structure-based tool to interpret the significance of kinase mutations in clinical next generation sequencing in cancer [0.03%]
基于结构的工具，解释癌症临床下一代测序中激酶突变的意义
Amith Rangarajan,Ilona Sviezhentseva,Emma Gunderson et al.
Amith Rangarajan et al.
Introduction: Clinical workflows to analyze variants of unknown significance (VUSs) found in clinical next generation sequencing (NGS) are labor intensive, requiring manual analysis of published data for each variant. The...
Cardiac toxicity and intervention strategies during thoracic cancer radiotherapy [0.03%]
胸部肿瘤放射治疗过程中心脏毒副反应及防护策略研究进展
Youjin Kong,Chao Yang,Lingling Xie et al.
Youjin Kong et al.
Radiation-induced heart disease (RIHD) represents a major dose-limiting complication of thoracic radiotherapy, with a multifaceted pathogenesis involving endothelial dysfunction, chronic oxidative stress, and progressive fibrotic remodeling...
Metastatic colon adenocarcinoma to the gingiva treated with spatial fractionation radiotherapy: a case report [0.03%]
空间分割放射治疗龈部转移性结肠腺癌一例报告
Xinyi Liu,Ke Xu,Quan Yao et al.
Xinyi Liu et al.
Metastatic colon adenocarcinoma to the gingiva is exceedingly rare, accounting for 1-3% of maxillofacial malignancies and usually associated with advanced disease and poor prognosis. This case report describes a 68-year-old woman diagnosed ...
Relationship between immunohistochemical markers and clinical pathological variables in clear cell renal cell carcinoma [0.03%]
透明细胞肾细胞癌免疫组织化学标志物与临床病理变量之间的关系
Pengshuai Liu,Junli Wei,Shubo Chen
Pengshuai Liu
Objective: To explore the factors associated with the immunohistochemical results in clear cell renal cell carcinoma (ccRCC). Methods: ...
Danfeng Li,Lifu Luo,Bo Yang et al.
Danfeng Li et al.
Retinal metastasis is an exceedingly rare manifestation of systemic cancer, accounting for less than 1% of ocular metastases. Lung adenocarcinoma is among the primary tumors that can metastasize to the retina, though such cases are seldom r...
A four-gene signature identified by integrated transcriptomic analysis for differential diagnosis and prognosis of uterine smooth muscle tumors [0.03%]
基于整合转录组分析鉴定的用于子宫平滑肌肿瘤鉴别诊断和预后判断的四基因标志物
Huiyi Hu,Yuanqun Chen,Bo Hong et al.
Huiyi Hu et al.
Introduction: Uterine leiomyomas (ULM) and uterine leiomyosarcomas (ULMS) are smooth muscle tumors of the uterus that share overlapping histopathological features but exhibit markedly different biological behaviors and cl...
Systematic literature review of real-world evidence on overall survival in cancer patients before and after the approval of anti-PD-(L)1 therapy [0.03%]
系统评价：抗PD-(L)1疗法获批前后肿瘤患者总生存率的现实世界证据
Dweeti Nayak,Katherine G Akers,Andrew M Frederickson et al.
Dweeti Nayak et al.
Background: The development and regulatory approval of anti-programmed death (ligand) 1 (anti-PD-(L)1) agents, based on positive clinical trial results, has dramatically changed clinical practice and treatment paths in on...